# Acclaro Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acclaro-medical

- Industry: Healthcare
- Headquarters: Smithfield, US
- Website: www.ultraclearlaser.com
- Total disclosed funding: $23M
- Latest round: Series B (May 29, 2025)
- Investors on record: 2

## About

Founded in 2018 and headquartered in Smithfield, US, Acclaro Medical focuses on advanced skin health solutions. Founded in 2018 and headquartered in Smithfield, US, Acclaro Medical focuses on advanced skin health solutions. In May 2025, Acclaro Medical raised USD 23 million in Series B funding led by  Accelmed, with participation from 3E Bioventures Capital. Acclaro Medical offers a range of advanced skin rejuvenation technologies under the UltraClear Laser brand. This includes proprietary services utilizing the 3DMIRACL laser and 3DIntelliPulse technology, designed to treat skin conditions such as deep wrinkles, scars, and age spots. The treatments are non-invasive and cater to a diverse clientele, addressing the needs of individuals across various skin types. UltraClear Laser's products are marketed in North America, Europe, and select Asian markets, targeting aesthetic clinics and medical practices that seek to enhance patient experiences in cosmetic dermatology. The revenue model for Acclaro Medical is centered on B2B transactions, primarily involving the sale of its advanced laser systems and consumables to aesthetic and medical practices. Clients directly purchase the UltraClear platform, which includes options for training and ongoing support services. The flagship products, including the 3DMIRACL and 3DIntelliPulse lasers, are critical to their service offering. Pricing is based on equipment and service agreements, ensuring that practices can integrate UltraClear’s technology into their operations efficiently. Looking ahead, Acclaro Medical plans to leverage the recent funding of USD 23.00 mn to accelerate its expansion in the skin health sector. The company is developing new products aimed at enhancing its existing offerings, although specific release dates have yet to be announced. Additionally, Acclaro Medical is targeting further market expansion, with plans to enter additional international regions by the end of 2025, enhancing its presence in the cosmetic dermatology market.

## Funding rounds

- Series B, May 29, 2025, $23M — Accelmed, 3E Bioventures Capital

## Investors

- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B